Literature DB >> 18050303

Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas.

Prakash Nair1, Katleen De Preter, Katleen DePreter, Jo Vandesompele, Frank Speleman, Raymond L Stallings.   

Abstract

Neuroblastoma (NBL), a pediatric tumor arising from precursor cells of the sympathetic nervous system, is characterized by numerous recurrent large-scale chromosomal imbalances. High resolution oligonucleotide array CGH analysis of NBL has previously identified microdeletions that are confined to the 5' UTR of the protein tyrosine phosphatase receptor D (PTPRD) gene, implicating this gene in the pathogenesis of these tumors. Here, we demonstrate that the 5' UTR of this gene, consisting of 11 noncoding exons, is also aberrantly spliced in >50% of NBL primary tumors and cell lines. The loss of exons from the 5' UTR region through aberrant splicing results in aberrant mRNA isoforms that are similar to those generated through microdeletions. The aberrant splicing or microdeletion of 5' UTR exons in such a high proportion of tumors indicates that loss of these exons dys-regulates the mRNA sequence. To further validate the role of PTPRD in NBL, we have examined the expression of this gene in normal fetal adrenal neuroblasts (the cell of origin of NBL) and in tumors from patients with either low stage or high stage disease. This gene is expressed at lower levels in high stage NBL tumors, particularly those with amplification of MYCN, relative to low stage tumors or normal fetal adrenal neuroblasts, consistent with the possibility that loss of the 5' UTR exons have destabilized the mRNA. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18050303     DOI: 10.1002/gcc.20521

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

Review 2.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

3.  Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.

Authors:  Maria Meehan; Laavanya Parthasarathi; Niamh Moran; Caroline A Jefferies; Niamh Foley; Elisa Lazzari; Derek Murphy; Jacqueline Ryan; Berenice Ortiz; Armida W M Fabius; Timothy A Chan; Raymond L Stallings
Journal:  Mol Cancer       Date:  2012-02-05       Impact factor: 27.401

4.  Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.

Authors:  Junko Takita; Yuyan Chen; Motohiro Kato; Kentaro Ohki; Yusuke Sato; Shigeru Ohta; Kanji Sugita; Riki Nishimura; Noriko Hoshino; Masafumi Seki; Masashi Sanada; Akira Oka; Yasuhide Hayashi; Seishi Ogawa
Journal:  Cancer Sci       Date:  2014-02-26       Impact factor: 6.716

5.  Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma.

Authors:  Ioana Cutcutache; Alice Yingting Wu; Yuka Suzuki; John Richard McPherson; Zhengdeng Lei; Niantao Deng; Shenli Zhang; Wai Keong Wong; Khee Chee Soo; Weng Hoong Chan; London Lucien Ooi; Roy Welsch; Patrick Tan; Steven G Rozen
Journal:  Gastric Cancer       Date:  2015-07-24       Impact factor: 7.370

6.  Protein tyrosine phosphatase receptor-type δ acts as a negative regulator suppressing breast cancer.

Authors:  Xiaotang Yu; Fan Zhang; Jun Mao; Ying Lu; Jiazhi Li; Wei Ma; Shujun Fan; Chunying Zhang; Qing Li; Bo Wang; Bo Song; Lianhong Li
Journal:  Oncotarget       Date:  2017-10-24

7.  Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.

Authors:  Lindi Chen; Angharad Humphreys; Lisa Turnbull; Angela Bellini; Gudrun Schleiermacher; Helen Salwen; Susan L Cohn; Nick Bown; Deborah A Tweddle
Journal:  Oncotarget       Date:  2016-12-27

8.  Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

Authors:  William P D Hendricks; Victoria Zismann; Karthigayini Sivaprakasam; Christophe Legendre; Kelsey Poorman; Waibhav Tembe; Nieves Perdigones; Jeffrey Kiefer; Winnie Liang; Valerie DeLuca; Mitchell Stark; Alison Ruhe; Roe Froman; Nicholas S Duesbery; Megan Washington; Jessica Aldrich; Mark W Neff; Matthew J Huentelman; Nicholas Hayward; Kevin Brown; Douglas Thamm; Gerald Post; Chand Khanna; Barbara Davis; Matthew Breen; Alexander Sekulic; Jeffrey M Trent
Journal:  PLoS Genet       Date:  2018-09-06       Impact factor: 5.917

Review 9.  Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets.

Authors:  Caroline E Nunes-Xavier; Laura Zaldumbide; Lorena Mosteiro; Ricardo López-Almaraz; Nagore García de Andoin; Pablo Aguirre; Maite Emaldi; Leire Torices; José I López; Rafael Pulido
Journal:  Front Cell Dev Biol       Date:  2021-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.